ABSTRACT
Objective To analyze the population characteristics, diagnostic characteristics and drug characteristics of patients with ovarian malignant tumor in the real world; To provide references for the clinical rational use of Fufang Kushen Injection.Methods Based on the electronic medical data warehouse of hospital information system of 39 hospitals from nationwide,the use of Fufang Kushen Injection in the treatment and diagnosis of electronic health data in patients with ovarian malignant tumor from August 2003 to December 2014 were extracted. Analysis of frequency and rate were based on the description of the demographic information, diagnosis information, records information such as the characteristics of prescription drugs. Result Data of 22 hospitals, including 1510 cases of patients with ovarian malignant tumor. The average age of patients was (54.93±12.75) years old, and obstetrics and gynecology department and oncology department had the most hospitalized patients, and outpatient admission is the most common hospitalized way. The single dose was (14.53±4.24)mL, and the course of treatment was (6.62±5.49)d.In the treatment of ovarian malignant tumors, combined western medicines were mainly anti-tumor chemotherapy drugs, immunomodulators, hepatoprotective agents, H1 receptor antagonists and electrolyte balance regulator, while combined TCM were clearing heat and antidote medicine, tonifying yang qi medicine, tonifying qi medicine, regulating qi medicine, and hemostatic medicine. The total effective rate was 47.85%. Conclusion Population characteristics of Fufang Kushen Injection in the treatment of ovarian malignant tumors are clear;and the real world clinical dosage, course of treatment with instructions related to define the scope of the basic varieties. Clinical combination has a wide range of drugs.
ABSTRACT
To analyze the clinical application features of Fufang Kushen injection in treating malignant esophageal tumors in the real world by using hospital information system database, and provide reference for clinical application of Fufang Kushen injection. The electronic medical data from 2 550 patients with malignant esophageal tumors using Fufang Kushen injection from 22 large-scale hospitals nationwide were extracted based on the hospital information system (HIS) established by Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences. Then the descriptive analysis based on frequency and rate was conducted for general characteristics, diagnostic characteristics, characteristics of dosage and medication information, characteristics of drug combination, and discharge outcome characteristics. The results showed that the average age of patients treated with Fufang Kushen injection for malignant esophageal tumors was 62.3 years old; more males than females; admitted to hospital mainly in department of cardiology, oncology and digestology first. The total efficiency was 47.15% based on the discharge outcome characteristics; the most common dosage was 10-20 mL for single use; the course of treatment was mainly 4-7 d; and the common drugs in drug combinations included dexamethasone, tropisetron injection, thymosin injection, compound amino acid injection, pantoprazole sodium injection, fluorouracil, et al. The characteristics of the crowd using Fufang Kushen injection to treat the malignant esophageal tumors were clear and in line with the general rule of malignant esophageal tumors; its clinical dosage and scope of treatment for malignant esophageal tumors in the real world were basically consistent with the specification; and the types of clinical drug use combinations were more extensive.
ABSTRACT
Considering technology,regulations and other factors,nowadays we still use the records of print instead of in digital.《Electric Signature Law》makes a new environments for the study of electric medical records system.It regulates the writing,originally form and the save of electric medical records,affirms its value of evidence in court and prescribes what is dependable electric signature.